Core Viewpoint - Galapagos NV is undergoing a planned separation into two independent entities, with Mr. Henry Gosebruch appointed as the founding CEO of the new subsidiary, SpinCo, which will focus on innovative medicines and is initially funded with approximately €2.45 billion in cash and cash equivalents [2][3]. Group 1: Leadership Changes - Dr. Paul Stoffels, the current CEO and Chair of the Board of Directors at Galapagos, plans to retire as CEO within the next 12 months but will remain as Chair, ensuring leadership continuity [1][3]. - The Board of Directors will search for a successor CEO for Galapagos, who will lead the company into its next phase of growth and innovation as a focused cell therapy company [3][4]. Group 2: SpinCo's Focus and Strategy - SpinCo will concentrate on building a pipeline of innovative medicines with demonstrated proof-of-concept, aiming to elevate the standard of care for patients through transformative transactions [2][3]. - The new entity will leverage a strong balance sheet and pursue opportunities that create significant value for shareholders [3][5]. Group 3: Background of Mr. Henry Gosebruch - Mr. Gosebruch has extensive experience in M&A, business development, and venture capital, previously serving as President and CEO at Neumora and Executive Vice President at AbbVie [6][7]. - At AbbVie, he was instrumental in completing over 100 business development transactions, including the acquisition of Allergan [7][8]. - His background includes over 20 years at J.P. Morgan, where he co-headed the North American M&A Group and worked on transactions exceeding $375 billion [8]. Group 4: Galapagos' Strategic Direction - Galapagos aims to transform into an R&D-driven biotech company with a focus on oncology, utilizing a decentralized manufacturing platform for cell therapies [4][9]. - The company is advancing its pipeline of potentially best-in-class assets, with ongoing Phase 2 clinical studies targeting aggressive hematological malignancies and solid tumors [4].

Core Points - Galapagos NV announced the departure of CFO and COO Thad Huston, effective August 1, 2025, for personal and professional reasons [1][2] - Huston joined Galapagos in 2023 to aid in its transformation into a cell therapy company, focusing on a decentralized cell therapy platform [2][3] - CEO Paul Stoffels expressed gratitude for Huston's contributions and emphasized the importance of a smooth transition before his departure [3] Company Overview - Galapagos NV is a global biotechnology company dedicated to transforming patient outcomes through innovative science [1] - The company is currently undergoing a transformation into a focused cell therapy business, leveraging its unique platform to deliver CAR-T therapy with a vein-to-vein time of seven days [3] Future Developments - Galapagos plans to announce Huston's successor in the coming months [2] - The company is also involved in a strategic separation into two public companies, which is expected to bring anticipated benefits and synergies [4]

Core Points - Galapagos NV has published its annual report for the financial year 2024 and announced its Annual Shareholders' Meeting (AGM) scheduled for April 29, 2025 [1][2] - The AGM agenda includes the appointment of Mr. Oleg Nodelman as Non-Executive Non-Independent Director and the confirmation of the statutory auditor for sustainability reporting [3] - The proposed separation of Galapagos into two publicly traded entities will not be discussed at the AGM, with an Extraordinary Shareholders' Meeting expected to be convened in mid-2025 regarding this matter [4] Company Overview - Galapagos is a biotechnology company operating in Europe and the U.S., focused on transforming patient outcomes through innovative science and technology [6] - The company aims to address high unmet medical needs and has developed a deep pipeline of best-in-class medicines, including a decentralized cell therapy manufacturing platform [6] - Galapagos is committed to anticipating future healthcare needs and ensuring that its innovations reach those who require them most [6]

Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders’ Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company. The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The ...

Product Development Risks - The company is heavily dependent on the success of its clinical-stage product candidates, including oncology candidates GLPG5101 and GLPG5301, and immunology candidates GLPG3667[21] - Clinical development is lengthy and expensive, with uncertain outcomes, and earlier study results may not predict future trial results[22] - The regulatory approval processes in the US and Europe are lengthy and unpredictable, potentially affecting the commercial viability of products in development[24] - The company may not be successful in expanding its oncology portfolio and building a pipeline of product candidates due to limited resources[23] Financial Performance and Market Conditions - The company has limited historical profit from product sales, making it difficult to assess future prospects and financial results[30] - The market price of the American Depositary Shares (ADSs) could be subject to wide fluctuations[31] Competition and Market Dynamics - The company faces significant competition in drug discovery and development, which could reduce or eliminate commercial opportunities[28] - Legislative and regulatory activity may exert downward pressure on potential pricing and reimbursement for approved product candidates[28] Collaboration and Legal Risks - The company relies on a global R&D collaboration with Gilead, with no assurance that it will deliver expected benefits[29] - The company may face increased risks of securities class action litigation and shareholder activism[32]

Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March:TD Cowen 45th Annual Healthcare Conference Date: Tuesday, March 4, 2025Location: Boston, MACorporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CETLive Webcast Link: HereBarclays 27th Annual Global He ...

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &amp, NASDAQ:GLPG) received a transparency notification and 13D filing from Tang Capital.  Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on February 14, 2025 on behalf of Mr. Kevin Tang, Tang Capital Management, LLC ("TCM"), Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), and Tang Capital Partners III, Inc. ("TCP III"), who noti ...

Galapagos NV (NASDAQ:GLPG) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sri Ramaswami - Senior Vice President and Global Head of Corporate Affairs & Investor Relations Paul Stoffels - Chair of the Board & Chief Executive Officer Thad Huston - Chief Financial Officer & Chief Operating Officer Valeria Cnossen - General Counsel Jeevan Shetty - Head of Clinical Development Oncology John Mellors - Head of Cell Therapy Discovery & Early Development Conference Call Participant ...

Transforming Patient Outcomes Through Life-changing Science and Innovation Full Year 2024 Results and Recent Business Update Earnings Call, February 13, 2025 Disclaimer This presentation contains "forward looking statements", all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "vision," " progress," "believe," "anticipate," "plan," "continue," "forward," "goal," "should," "expect," "outlook," "estimate," "next ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers ...